In an editorial for Science, Prof. Sangeeta Bhatia, Prof. Emerita Nancy Hopkins and President Emerita Susan Hockfield underscore the importance of addressing the underrepresentation of women and minorities in tech transfer. “The discoveries women and minority researchers are making today have great potential as a force for good in the world,” they write, “but reaching that potential is only possible if paths to real-world applications are open to everybody.”
Prof. Linda Griffith is on a mission to change the conversation about endometriosis “from one of women’s pain to one of biomarkers, genetics and molecular networks,” writes Rachel E. Gross for The New York Times. “The endometrium is inherently regenerative,” says Griffith. “So studying it, you’re studying a regenerative process — and how it goes wrong, in cases.”
Prof. Emerita Nancy Hopkins speaks with Rebecca Sohn of STAT about the Boston Biotech Working Group’s goal of increasing the number of women leaders and entrepreneurs in biotech and her hopes for the future of women in biotech and the sciences. “You want people to feel that they are free to participate in all the things wherever it leads them,” says Hopkins. “So I think the goal is just that people who really want to do this [pursue biotech] don’t face any greater barrier than anybody else. That everybody has equal access and education to do as they want to.”
To better understand what gives mucus its disease-protecting properties, MIT researchers created synthetic mucins, writes Forbes contributor Jackie Rocheleau. Understanding the antimicrobial properties of mucus “could offer a whole new way of treating infectious disease,” says Prof. Laura Kiessling.
Singapore-MIT Alliance for Research and Technology (SMART) researchers have developed a new lab-free immune profiling assay that can be used “to better profile aggressive, rapidly changing host immune response in cases of infection, for example COVID-19,” reports HealthCare Asia Daily.
A new assay developed by researchers from the Critical Analytics for Manufacturing Personalized-Medicine (CAMP), an Interdisciplinary Research Group (IRG) at the Singapore-MIT Alliance for Research and Technology (SMART), can profile the “rapidly changing host immune response in case of infection, in a departure from existing methods that focus on detecting the pathogens themselves,” reports the Scientific Inquirer.
Writing for The New York Times, visiting scientist Mark Trusheim and Peter Bach of Memorial Sloan Kettering Cancer Center explore how to lower the cost of biologic drugs. “Prices of new drugs will continue to make headlines, as well they should,” they write. “But we must fix the problem that older biologic drugs have perpetually high prices, and do so by passing a law that ensures that at the appropriate time their prices fall fast, and they fall far.”
Dr. Francis Collins, director of the NIH, spotlights Prof. Ed Boyden’s work developing a new technology that “enables researchers for the first time to study an intact tissue sample and track genetic activity on the spot within a cell’s tiniest recesses, or microenvironments—areas that have been largely out of reach until now.”
Wired reporter Will Knight spotlights how MIT researchers built a machine learning system that can help predict which patients are most likely to develop breast cancer. “What the AI tools are doing is they're extracting information that my eye and my brain can't,” says Constance Lehman, a professor of radiology at Harvard Medical School and division chief of breast imaging at MGH.
Boston Globe reporter Jon Chesto writes that MIT, Harvard, several research hospitals and life-sciences companies have selected a site for a new biologics manufacturing and innovation center. The project is aimed at expediting “discoveries for biotech treatments in university labs by allowing researchers to bypass the long waits that are common at contract manufacturers,” writesChesto.
A new study by MIT researchers finds that “changes in coronavirus levels in wastewater preceded rises and falls in positive test results by four to 10 days,” reports Kim Tingley for The New York Times. The findings suggest that “sewage surveillance could play an important role in helping contain the pandemic.”
Prof. Eric Alm speaks with New York Times Magazine reporter Kim Tingley about how studying wastewater can provide public health officials with advance warning of an uptick in coronavirus cases. “If you want to really understand what’s going on in a city on a basic chemical, biological level, you should be looking at the wastewater," says Alm.
Reporting for WCVB-TV, Katie Thompson highlights a new study by MIT researchers that examines the role of super-spreading events in the Covid-19 pandemic. "The main idea is that most people generate zero or one cases, but it's the people generating hundreds of cases that we should perhaps be worried about," says postdoc Felix Wong said.
Prof. James Collins speaks with Boston 25 reporter Julianne Lima about the growing issue of antibiotic resistant bacteria and his work using AI to identify new antibiotics. Collins explains that a new platform he developed with Prof. Regina Barzilay uncovered “a host of new antibiotics including one that we call halicin that has remarkable activity against multi drug-resistant pathogens.”
A new study by MIT researchers finds that super-spreading events are larger drivers of the Covid-19 pandemic than originally thought, reports Carey Goldberg for WBUR. “We found in our study that super-spreading events can indeed be a major driver of the current pandemic,” says postdoc Felix Wong. “Most people generate zero or one cases, but it's the people generating hundreds of cases that we really should be worried about.”